134 related articles for article (PubMed ID: 38728485)
1. CDCA3 is a potential biomarker for glioma malignancy and targeted therapy.
Han C; Liu S; Ji Y; Hu Y; Zhang J
Medicine (Baltimore); 2024 May; 103(19):e38066. PubMed ID: 38728485
[TBL] [Abstract][Full Text] [Related]
2. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic Profiling Identifies a Glucose-Related Risk Signature for the Malignancy of Glioma and the Survival of Patients.
Zhao S; Cai J; Li J; Bao G; Li D; Li Y; Zhai X; Jiang C; Fan L
Mol Neurobiol; 2017 Dec; 54(10):8203-8210. PubMed ID: 27900679
[TBL] [Abstract][Full Text] [Related]
4. Translating bioinformatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis.
Itzel T; Scholz P; Maass T; Krupp M; Marquardt JU; Strand S; Becker D; Staib F; Binder H; Roessler S; Wang XW; Thorgeirsson S; Müller M; Galle PR; Teufel A
Bioinformatics; 2015 Jan; 31(2):216-24. PubMed ID: 25236463
[TBL] [Abstract][Full Text] [Related]
5. TUBA1C expression promotes proliferation by regulating the cell cycle and indicates poor prognosis in glioma.
Gui S; Chen P; Liu Y; Chen Q; Cheng T; Lv S; Zhou T; Song Z; Xiao J; He W; Yuan S; Cheng Z
Biochem Biophys Res Commun; 2021 Nov; 577():130-138. PubMed ID: 34517210
[TBL] [Abstract][Full Text] [Related]
6. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
7. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
8. Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer.
Xu Y; Shen M; Peng Y; Liu L; Tang L; Yang T; Pu D; Tan W; Zhang W; Liu S
Biomed Res Int; 2022; 2022():4632453. PubMed ID: 36082153
[TBL] [Abstract][Full Text] [Related]
9. CDCA3 is a potential prognostic marker that promotes cell proliferation in gastric cancer.
Zhang Y; Yin W; Cao W; Chen P; Bian L; Ni Q
Oncol Rep; 2019 Apr; 41(4):2471-2481. PubMed ID: 30816466
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of CDCA3 in kidney renal papillary cell carcinoma.
Li H; Li M; Yang C; Guo F; Deng S; Li L; Ma T; Yan J; Wu H; Li X
Aging (Albany NY); 2021 Dec; 13(23):25466-25483. PubMed ID: 34905505
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiles for insular low-grade gliomas with putamen involvement.
Zhou C; Wang Y; Liu X; Liang Y; Fan Z; Jiang T; Wang Y; Wang L
J Neurooncol; 2018 Jul; 138(3):659-666. PubMed ID: 29556911
[TBL] [Abstract][Full Text] [Related]
12. RAB34 was a progression- and prognosis-associated biomarker in gliomas.
Wang HJ; Gao Y; Chen L; Li YL; Jiang CL
Tumour Biol; 2015 Mar; 36(3):1573-8. PubMed ID: 25501506
[TBL] [Abstract][Full Text] [Related]
13. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
14. Adaptor Protein Complex 1 Sigma 3 Is Highly Expressed in Glioma and Could Enhance Its Progression.
Ye T; Cheng Y; Li C
Comput Math Methods Med; 2021; 2021():5086236. PubMed ID: 34367317
[TBL] [Abstract][Full Text] [Related]
15. Integrated Gene Expression and Methylation Analyses Identify DLL3 as a Biomarker for Prognosis of Malignant Glioma.
Maimaiti A; Wang X; Hao Y; Jiang L; Shi X; Pei Y; Feng Z; Kasimu M
J Mol Neurosci; 2021 Aug; 71(8):1622-1635. PubMed ID: 33713320
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas.
Liu Y; Hu H; Zhang C; Wang H; Zhang W; Wang Z; Li M; Zhang W; Zhou D; Jiang T
Oncotarget; 2015 Nov; 6(35):38257-69. PubMed ID: 26468983
[TBL] [Abstract][Full Text] [Related]
17. Integrated bioinformatics analysis and experimental validation identified CDCA families as prognostic biomarkers and sensitive indicators for rapamycin treatment of glioma.
Li R; Chen Y; Yang B; Li Z; Wang S; He J; Zhou Z; Li X; Li J; Sun Y; Guo X; Wang X; Wu Y; Zhang W; Guo G
PLoS One; 2024; 19(1):e0295346. PubMed ID: 38181024
[TBL] [Abstract][Full Text] [Related]
18. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
19. Computational screening of potential glioma-related genes and drugs based on analysis of GEO dataset and text mining.
Jiang Z; Shi Y; Tan G; Wang Z
PLoS One; 2021; 16(2):e0247612. PubMed ID: 33635875
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest.
Uchida F; Uzawa K; Kasamatsu A; Takatori H; Sakamoto Y; Ogawara K; Shiiba M; Tanzawa H; Bukawa H
BMC Cancer; 2012 Jul; 12():321. PubMed ID: 22839099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
